Inhibition of IL-17 receptor A did not produce a treatment effect in subjects with asthma. The results of the high-reversibility subgroup analysis are of uncertain significance, requiring further study of brodalumab in this asthma subpopulation. Clinical trial registered with www.clinicaltrials.gov (NCT01199289).

No abstract

In this population, first- and second-course persistence was similar among anti-TNF therapies. First-course discontinuation due to adverse events was lower with etanercept compared with infliximab.

BACKGROUND: High bronchodilator reversibility in adult asthma is associated with distinct clinical characteristics. Th is analysis compares lung function, biomarker profi les, and disease control in patients with high reversibility (HR) and low reversibility (LR) asthma.

Increased RA disease activity and disability were each associated with a significantly increased SIE risk in the RADIUS 1 cohort, which could not be completely accounted for by disability.